甲状腺激素和25-基维生素D3:对脏酸盐运输的协同和对抗作用
概括
副甲状腺激素 (PTH) 和25-基胆 (25-HCC) 共同作用,调节大鼠的酸盐分泌. 高剂量的PTH单独可以引起酸性尿,但较低剂量需要25-HCC.
科学领域:
- 内分泌学 在内分泌学.
- 脏生理学 脏生理学
- 矿物质的新陈代谢.
背景情况:
- 副甲状腺激素 (PTH) 和维生素D是和平衡的关键调节剂.
- 酸盐分泌中的PTH和维生素D代谢物之间的相互作用是复杂的.
- 了解这些相互作用对于管理矿物质不平衡至关重要.
研究的目的:
- 研究不同剂量的副甲状腺激素 (PTH) 和25-hydroxycholecalciferol (25-HCC) 对脏酸盐分泌的影响.
- 确定PTH和25-HCC在酸盐调节中的协同作用或独立作用.
- 在受控动物模型中建立剂量依赖的反应.
主要方法:
- 利用甲状腺瘤切除,维生素D贫乏的老鼠来消除内源激素的影响.
- 用25-HCC和PTH的分级剂量,单独或组合,通过连续输液.
- 监测尿路酸盐分泌,以应对荷尔蒙治疗.
主要成果:
- 低剂量25-HCC (1单位/小时) 仅在与低剂量PTH (0.2单位/小时) 结合时诱导抗素尿;单独没有影响酸盐分泌.
- 适量PTH (2.0单位/小时) 需要同时服用25-HCC (1单位/小时) 来引起酸性尿.
- 高剂量的PTH (5单位/小时) 即使没有25-HCC,也会引起酸化,这表明剂量依赖的效果.
结论:
- 通过PTH调节酸盐分泌,受到25-HCC在PTH次药理水平的存在和剂量的显著影响.
- 在PTH和25-HCC之间存在协同作用,以维持低度的酸盐平衡.
- 药理用PTH剂量可以超过25-HCC的要求,促进酸盐分泌.
更多相关视频
相关概念视频
Hormones and Bone Tissue
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


